In Depth 11 Oct 2021 A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […] October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2019 Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […] August 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of Oxford-based […] March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2019 Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies that are fused with proteins that modify the immune system to fight diseases such as cancer. For example, this treatment can bind to tumors and activate […] January 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 Another Huge Acquisition Sees CAR-T Stocks Jump – Except for Celyad Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire Juno: Cellectis rides the wave but Celyad misses it. Shortly after the mega-acquisition of Kite by Gilead, the second prettiest girl at the CAR-T party, Juno Therapeutics, has accepted the advances of Celgene in a $9Bn (€7.4Bn) acquisition. This represents a bullish […] January 23, 2018 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […] October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Evotec closes the year partnering with Celgene to treat Alzheimer’s Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug discovery CRO based in Germany that has managed to sign partnerships with some of the biggest names in Biotech. In addition to previous deals with Bayer, Merck, […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email